Amgen wants in on obesity. But it’s still working on rare disease, too

Am­gen tout­ed its rare dis­ease strat­e­gy on Thurs­day, high­light­ing the fi­nan­cial po­ten­tial of both cur­rent block­busters and oth­er drugs in its pipeline.

The spot­light on rare dis­eases fol­lows the com­ple­tion of its $28 bil­lion ac­qui­si­tion of Hori­zon Ther­a­peu­tics in 2023. Am­gen is now work­ing to in­te­grate Hori­zon and its pipeline fol­low­ing the re­cent ad­di­tion of rare dis­ease as the fourth pil­lar of its R&D fo­cus.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.